Abstract
The need for greater reductions in LDL cholesterol, although remaining to be proven as clinically beneficial, continues to drive the development of either higher doses of currently approved and marketed statins or the development of new, more effective agents.
MeSH terms
-
Atorvastatin
-
Cholesterol, LDL / metabolism
-
Dose-Response Relationship, Drug
-
Fatty Acids, Monounsaturated / administration & dosage
-
Fluorobenzenes / administration & dosage
-
Fluvastatin
-
Heptanoic Acids / administration & dosage
-
Humans
-
Hypolipidemic Agents / administration & dosage*
-
Indoles / administration & dosage
-
Lovastatin / administration & dosage
-
Pravastatin / administration & dosage
-
Pyridines / administration & dosage
-
Pyrimidines*
-
Pyrroles / administration & dosage
-
Rosuvastatin Calcium
-
Simvastatin / administration & dosage
-
Sulfonamides*
Substances
-
Cholesterol, LDL
-
Fatty Acids, Monounsaturated
-
Fluorobenzenes
-
Heptanoic Acids
-
Hypolipidemic Agents
-
Indoles
-
Pyridines
-
Pyrimidines
-
Pyrroles
-
Sulfonamides
-
Fluvastatin
-
Rosuvastatin Calcium
-
Lovastatin
-
Atorvastatin
-
Simvastatin
-
cerivastatin
-
Pravastatin